In this very comprehensive video, Prof. Kenneth Cusi, USA, reviews the guidelines on NAFLD that are currently being updated. He also shares highlights on the rationale of PPARs in NASH and discusses the clinical trials with Pioglitazone. He addresses the positive results as well as the misconceptions and barriers for using PPAR-γ in NASH.

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In

17 − fourteen =